NASDAQ:CLSD Clearside Biomedical - CLSD Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Clearside Biomedical, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $0.96 0.00 (-0.31%) (As of 03/30/2023 04:32 PM ET) Add Compare Share Share Today's Range$0.95▼$0.9850-Day Range$0.93▼$1.5452-Week Range$0.90▼$2.54Volume87,361 shsAverage Volume202,576 shsMarket Capitalization$58.72 millionP/E RatioN/ADividend YieldN/APrice Target$6.00 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Clearside Biomedical MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside531.6% Upside$6.00 Price TargetShort InterestHealthy0.70% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.43Based on 2 Articles This WeekInsider TradingSelling Shares$73,943 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($0.60) to ($0.63) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.90 out of 5 starsMedical Sector724th out of 999 stocksPharmaceutical Preparations Industry358th out of 489 stocks 3.5 Analyst's Opinion Consensus RatingClearside Biomedical has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $6.00, Clearside Biomedical has a forecasted upside of 531.6% from its current price of $0.95.Amount of Analyst CoverageClearside Biomedical has only been the subject of 3 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.70% of the float of Clearside Biomedical has been sold short.Short Interest Ratio / Days to CoverClearside Biomedical has a short interest ratio ("days to cover") of 1.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Clearside Biomedical has recently increased by 8.70%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldClearside Biomedical does not currently pay a dividend.Dividend GrowthClearside Biomedical does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CLSD. Previous Next 1.9 News and Social Media Coverage News SentimentClearside Biomedical has a news sentiment score of 0.43. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Clearside Biomedical this week, compared to 1 article on an average week.Search InterestOnly 2 people have searched for CLSD on MarketBeat in the last 30 days. This is a decrease of -88% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Clearside Biomedical to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Clearside Biomedical insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $73,943.00 in company stock.Percentage Held by Insiders12.00% of the stock of Clearside Biomedical is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 20.07% of the stock of Clearside Biomedical is held by institutions. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Clearside Biomedical are expected to decrease in the coming year, from ($0.60) to ($0.63) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Clearside Biomedical is -1.73, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Clearside Biomedical is -1.73, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioClearside Biomedical has a P/B Ratio of 5.28. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Clearside Biomedical (NASDAQ:CLSD) StockClearside Biomedical, Inc. is a biopharmaceutical company, which delivers therapies to the back of the eye through the suprachoroidal space. Its pipeline include CLS-AX, Integrin Inhibitor, and gene therapy. The company was founded by Samir Kumar Patel, Vladimir Zarnitsyn, Mark Prausnitz, Daniel H. White, and Henry F. Edelhauser in May 2011 and is headquartered in Alpharetta, GA.Read More Receive CLSD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Clearside Biomedical and its competitors with MarketBeat's FREE daily newsletter. Email Address CLSD Stock News HeadlinesMarch 11, 2023 | benzinga.comClearside Biomedical Stock (NASDAQ:CLSD), Analyst Ratings, Price Targets, PredictionsMarch 11, 2023 | finance.yahoo.comClearside Biomedical, Inc. (NASDAQ:CLSD) Q4 2022 Earnings Call TranscriptMarch 30, 2023 | The Oxford Club (Ad)My No. 1 dividend stock for a LIFETIME of income.Few people realize this… But dividends account for up to 90% of the stock market's returns over the past century! I think it's a crying shame folks don't know how powerful dividends are.March 10, 2023 | markets.businessinsider.comWedbush Reaffirms Their Buy Rating on Clearside Biomedical (CLSD)March 10, 2023 | msn.comWhat 5 Analyst Ratings Have To Say About Clearside BiomedicalMarch 10, 2023 | finanznachrichten.deClearside Biomedical, Inc.: Clearside Biomedical Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate UpdateMarch 10, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Clearside Biomedical (CLSD) and Applied Molecular Transport (AMTI)March 9, 2023 | msn.comClearside Biomedical GAAP EPS of -$0.16 misses by $0.04, revenue of $0.3M beats by $0.2MMarch 30, 2023 | Stansberry Research (Ad)The gold catalyst we’ve waited forIf you thought the SVB meltdown was bad… watch out. Because even bigger red flag just appeared. This signal proves that a recession is likely right around the corner. It will take most by surprise. Stocks will crash. Millions will go jobless, and lose their homes. But there is ONE important step you should take today to make sure you come out the other side OK. March 9, 2023 | finance.yahoo.comClearside Biomedical Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate UpdateMarch 9, 2023 | finance.yahoo.comClearside Biomedical Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate UpdateMarch 9, 2023 | finance.yahoo.comClearside Biomedical, Inc. (CLSD) Reports Q4 Loss, Tops Revenue EstimatesMarch 8, 2023 | msn.comA Preview Of Clearside Biomedical's EarningsFebruary 23, 2023 | finance.yahoo.comClearside Biomedical to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Corporate Update on Thursday, March 9, 2023February 21, 2023 | finance.yahoo.comClearside Biomedical Announces Positive Data Presentations on CLS-AX OASIS Clinical Trial and Use of SCS Microinjector® Presented at the Angiogenesis and Macula Society Annual MeetingsFebruary 15, 2023 | markets.businessinsider.comAnalysts Are Bullish on Top Healthcare Stocks: Clearside Biomedical (CLSD), CSL (CMXHF)February 7, 2023 | finance.yahoo.comClearside Biomedical OASIS Data to be Presented at Multiple Upcoming Medical Meetings in February 2023February 6, 2023 | finance.yahoo.comClearside Biomedical Announces Leadership Team UpdateFebruary 3, 2023 | markets.businessinsider.comAnalyst Expectations for Clearside Biomedical's FutureFebruary 2, 2023 | seekingalpha.comClearside gains 12% as eye disease therapy cuts need for additional treatmentFebruary 2, 2023 | finance.yahoo.comClearside Biomedical Announces Positive 6-Month Results from OASIS Extension Study with Suprachoroidal CLS-AX (axitinib injectable suspension) in Wet AMDJanuary 1, 2023 | forbes.comClearside BiomedicalDecember 22, 2022 | finance.yahoo.comCompanies Like Clearside Biomedical (NASDAQ:CLSD) Can Afford To Invest In GrowthNovember 22, 2022 | finance.yahoo.comClearside Biomedical to Participate in Multiple Upcoming Investor and Ophthalmology Conferences in November and December 2022November 11, 2022 | finance.yahoo.comClearside Biomedical Third Quarter 2022 Earnings: Beats ExpectationsNovember 10, 2022 | finance.yahoo.comAnalyst Bumps Up Clearside Biomedical Target Price After Encouraging Trial DataNovember 10, 2022 | benzinga.comThinking about buying stock in Digital Turbine, Purple Innovation, Clearside Biomedical, Rivian Automotive, or ZipRecruiter?See More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive CLSD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Clearside Biomedical and its competitors with MarketBeat's FREE daily newsletter. Email Address CLSD Company Calendar Last Earnings11/10/2021Today3/30/2023Next Earnings (Estimated)5/10/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CLSD CUSIPN/A CIK1539029 Webwww.clearsidebio.com Phone(678) 270-3631Fax678-270-4033Employees34Year FoundedN/APrice Target and Rating Average Stock Price Forecast$6.00 High Stock Price Forecast$8.00 Low Stock Price Forecast$4.00 Forecasted Upside/Downside+525.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($0.55) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-32,950,000.00 Net Margins-2,482.82% Pretax Margin-2,482.82% Return on Equity-153.06% Return on Assets-75.83% Debt Debt-to-Equity RatioN/A Current Ratio8.54 Quick Ratio8.54 Sales & Book Value Annual Sales$1.33 million Price / Sales44.39 Cash FlowN/A Price / Cash FlowN/A Book Value$0.18 per share Price / Book5.33Miscellaneous Outstanding Shares61,364,000Free Float54,000,000Market Cap$58.91 million OptionableOptionable Beta1.95 Key ExecutivesGeorge M. LasezkayPresident, Chief Executive Officer & DirectorCharles A. DeignanChief Financial OfficerRafael V. AndinoSenior VP-Engineering & ManufacturingSusan L. CoultasChief Clinical OfficerLeslie B. ZacksSecretary & Chief Compliance OfficerKey CompetitorsHomology MedicinesNASDAQ:FIXXImmunomeNASDAQ:IMNMGain TherapeuticsNASDAQ:GANXViracta TherapeuticsNASDAQ:VIRXSyros PharmaceuticalsNASDAQ:SYRSView All CompetitorsInsiders & InstitutionsMillennium Management LLCSold 105,648 shares on 2/15/2023Ownership: 0.089%Morgan StanleySold 75,031 shares on 2/15/2023Ownership: 0.071%Two Sigma Investments LPSold 67,374 shares on 2/14/2023Ownership: 0.168%Water Island Capital LLCBought 47,000 shares on 2/14/2023Ownership: 0.078%Susquehanna International Group LLPSold 123,700 shares on 2/14/2023Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions CLSD Stock - Frequently Asked Questions Should I buy or sell Clearside Biomedical stock right now? 4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Clearside Biomedical in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" CLSD shares. View CLSD analyst ratings or view top-rated stocks. What is Clearside Biomedical's stock price forecast for 2023? 4 equities research analysts have issued 1-year price targets for Clearside Biomedical's shares. Their CLSD share price forecasts range from $4.00 to $8.00. On average, they expect the company's stock price to reach $6.00 in the next year. This suggests a possible upside of 527.0% from the stock's current price. View analysts price targets for CLSD or view top-rated stocks among Wall Street analysts. How have CLSD shares performed in 2023? Clearside Biomedical's stock was trading at $1.12 at the beginning of 2023. Since then, CLSD stock has decreased by 14.6% and is now trading at $0.9570. View the best growth stocks for 2023 here. Are investors shorting Clearside Biomedical? Clearside Biomedical saw a increase in short interest in March. As of March 15th, there was short interest totaling 351,200 shares, an increase of 8.7% from the February 28th total of 323,100 shares. Based on an average trading volume of 237,900 shares, the short-interest ratio is presently 1.5 days. Currently, 0.7% of the company's stock are sold short. View Clearside Biomedical's Short Interest. When is Clearside Biomedical's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 10th 2023. View our CLSD earnings forecast. How were Clearside Biomedical's earnings last quarter? Clearside Biomedical, Inc. (NASDAQ:CLSD) announced its earnings results on Wednesday, November, 10th. The company reported ($0.08) earnings per share for the quarter, beating the consensus estimate of ($0.09) by $0.01. The firm earned $3.07 million during the quarter, compared to the consensus estimate of $3.32 million. Clearside Biomedical had a negative trailing twelve-month return on equity of 153.06% and a negative net margin of 2,482.82%. During the same quarter in the previous year, the business earned ($0.05) earnings per share. What other stocks do shareholders of Clearside Biomedical own? Based on aggregate information from My MarketBeat watchlists, some companies that other Clearside Biomedical investors own include Northwest Biotherapeutics (NWBO), Ocular Therapeutix (OCUL), Matinas BioPharma (MTNB), ADMA Biologics (ADMA), Melinta Therapeutics (MLNT), Organigram (OGI), Zosano Pharma (ZSAN), Sorrento Therapeutics (SRNE), Miragen Therapeutics (MGEN) and Gran Tierra Energy (GTE). When did Clearside Biomedical IPO? (CLSD) raised $50 million in an IPO on Thursday, June 2nd 2016. The company issued 7,200,000 shares at $7.00 per share. Cowen and Company and Stifel served as the underwriters for the IPO and Needham & Company, Wedbush PacGrow was co-manager. What is Clearside Biomedical's stock symbol? Clearside Biomedical trades on the NASDAQ under the ticker symbol "CLSD." Who are Clearside Biomedical's major shareholders? Clearside Biomedical's stock is owned by many different retail and institutional investors. Top institutional investors include Renaissance Technologies LLC (0.98%), Johnson & Johnson (0.28%), Assenagon Asset Management S.A. (0.28%), Two Sigma Investments LP (0.17%), Northeast Financial Consultants Inc (0.14%) and Hamilton Lane Advisors LLC (0.11%). Insiders that own company stock include Bradford T Whitmore, Bradford T Whitmore, Charles A Deignan, Clay Thorp, George M Lasezkay, George M Lasezkay, Nancy J Hutson, Richard T Burke, Thomas Ciulla and William D Humphries. View institutional ownership trends. How do I buy shares of Clearside Biomedical? Shares of CLSD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Clearside Biomedical's stock price today? One share of CLSD stock can currently be purchased for approximately $0.96. How much money does Clearside Biomedical make? Clearside Biomedical (NASDAQ:CLSD) has a market capitalization of $58.72 million and generates $1.33 million in revenue each year. The company earns $-32,950,000.00 in net income (profit) each year or ($0.55) on an earnings per share basis. How can I contact Clearside Biomedical? Clearside Biomedical's mailing address is 900 NORTH POINT PARKWAY SUITE 200, ALPHARETTA GA, 30005. The official website for the company is www.clearsidebio.com. The company can be reached via phone at (678) 270-3631, via email at charlie.deignan@clearsidebio.com, or via fax at 678-270-4033. This page (NASDAQ:CLSD) was last updated on 3/30/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.